Previous 10 | Next 10 |
Aeglea BioTherapeutics ( NASDAQ: AGLE ) stock fell ~5% on Oct. 4 after the company said the U.S. Food and Drug Administration (FDA) placed a phase 1/2 trial of pegtarviliase on partial clinical hold for the enrollment of patients less than 18 years of age. ...
Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program PR Newswire AUSTIN, Texas , Oct. 4, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing ...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 PR Newswire AUSTIN, Texas , Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical...
Aeglea BioTherapeutics ( NASDAQ: AGLE ), a biotech focused on rare metabolic diseases, announced Wednesday that the company’s current President, Chief Executive, and director of the board, Anthony Quinn, would step down with immediate effect. The leadership transiti...
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring PR Newswire Prioritizing Resources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2 Trial in Homocystinuria with Interim Clinical Data Expected in Q4 of 2022 ...
3 Penny Stocks to Add to Your Watchlist This Week If you’re looking for penny stocks that are worth buying, there are a few things you should look for. First, find stocks that are trading with your strategy in mind. Second, research the company to make sure it could have movement...
Do you want to find penny stocks to buy? If you know what you’re looking for, putting together a strong list of stocks to watch is easy. Whether you’re looking for the most active names, higher volume stocks, or something else, a theme is an excellent thing to have when you be...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday! There’s public stock offerings, earnings reports, inve...
Aeglea BioTherapeutics ( NASDAQ: AGLE ) on Thursday said Europe's drug regulator had validated the company's marketing authorization application for enzyme pegzilarginase for the treatment of Arginase 1 deficiency. Shares of the micro-cap clinical-stage biotech soared 57.5% ...
News, Short Squeeze, Breakout and More Instantly...
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire Company will begin trading on Nasdaq under trading sy...
2023-11-20 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β...